RESUMEN
Newborn screening is a medical population-based preventive measure for the early detection and initiation of therapy for all newborns with treatable endocrine and metabolic diseases. Left untreated, these diseases may lead to severe disabilities or even death. Target diseases have to meet the Wilson and Junger criteria on screening. A high sensitivity and specificity is ensured by an excellent analytic process. High process quality is achieved by offering newborn screening to all newborns and by clarifying pathologic findings very quickly. Therefore, in some federal states tracking centers have been established. Nationwide evaluation of process quality is annually performed and published online. The long-term outcome of diseased children has been investigated on a population-based level in Bavaria and at the University of Heidelberg in other studies. Between 2004 and 2012, 6.1 million children were screened (this is equivalent to 99 % of all newborns). The percentage of pathologic findings was 0.6 %. One out of 1300 children was affected by a target disease. For 90 % of these children, therapy started within the first 2 weeks of life. Studies on the long-term outcome show a positive effect on the course of disease, development of children, and the quality of life. In these studies, further challenges in care such as the first information given to parents regarding a pathologic finding or the care of adolescents with less compliance could also be identified. Newborn screening is an established preventive measure. With regard to ethical criteria and effectiveness, continuous evaluation of the process quality and the long-term outcome assure a high quality of the screening process.
Asunto(s)
Predisposición Genética a la Enfermedad/epidemiología , Predisposición Genética a la Enfermedad/genética , Pruebas Genéticas/estadística & datos numéricos , Errores Innatos del Metabolismo/epidemiología , Errores Innatos del Metabolismo/prevención & control , Tamizaje Neonatal/métodos , Femenino , Pruebas Genéticas/métodos , Alemania/epidemiología , Humanos , Recién Nacido , Masculino , Errores Innatos del Metabolismo/genética , Reproducibilidad de los Resultados , Prevención Secundaria/métodos , Prevención Secundaria/estadística & datos numéricos , Sensibilidad y EspecificidadRESUMEN
Insulin secretion from pancreatic ß-cells is tightly regulated to maintain fasting blood glucose level between 3.5-5.5 mmol/l. In hyperinsulinaemic hypoglycaemia (HH) insulin secretion becomes unregulated so that insulin secretion persists despite low blood glucose levels. HH can be due to a large number of causes and recent advances in genetics have begun to provide novel insights into the molecular mechanisms of HH. Defects in key genes involved in regulating insulin secretion have been linked to HH. The most severe forms of HH are clinically observed in the newborn period whereas in adults an insulinoma is the commonest cause of HH. This review provides an overview on the molecular mechanisms leading to HH in children and adults, it describes the clinical presentation and diagnosis, and finally the treatment options for the different forms of HH are discussed.
Asunto(s)
Hiperinsulinismo/complicaciones , Hipoglucemia/complicaciones , Animales , Humanos , Hiperinsulinismo/congénito , Hiperinsulinismo/diagnóstico , Hiperinsulinismo/terapia , Hipoglucemia/congénito , Hipoglucemia/diagnóstico , Hipoglucemia/terapia , Insulina/metabolismo , Secreción de Insulina , Células Secretoras de Insulina/metabolismo , Células Secretoras de Insulina/patología , Periodo PosprandialRESUMEN
10 of the 13 federal states presented their structures, implementation methods and results as part of the nationwide workshop for children's preventative medicine and early recognition projects for Germany on 9th September 2011 in Frankfurt am Main. This was the first time a full overview of all programmes of this kind in Germany has been possible. The programmes and data from these 10 presentations were analysed and compared. Despite the many differences between the legal frameworks and structural implementation, the programmes also displayed similarities in the implementation and in the problems which arise. Significantly improved participation rates for early recognition check-ups have been achieved in the context of the programmes. Previously, only a few detailed evaluations for the detection of risks to children's welfare and other effects such as vaccination rates and improvements in children's health through more advice and care were available.
Asunto(s)
Servicios de Salud del Niño/tendencias , Protección a la Infancia/tendencias , Pediatría/tendencias , Medicina Preventiva/tendencias , Niño , HumanosRESUMEN
Congenital hyperinsulinism (CHI), syn. nesidioblastosis, is the most frequent cause of persistent, recurrent hypoglycemia in infancy. One third of patients show a single circumscribed focus. Enucleation of the focus and the removal of all affected ß-cells with preservation of healthy tissue is the treatment of choice. The intrapancreatic choledochus as well as the ductus pancreaticus major must remain intact. The diagnostic gold standard is 18F-DOPA-PET/CT. Intraoperative sonography is carried out to correctly visualize the focus preoperatively localized by PET/CT in situ during the operation. The enucleation of the focus was carried out 3 - 20 days after PET/CT in 5 patients at an age of 3.5 - 14 months. Intraoperative ultrasound was carried out with high-capacity devices of different manufacturers under use of broadband probes (9 - 14 MHz). The localization by intraoperative ultrasound was accurate in all 5 patients with focal CHI, with regard to the intraoperative localization as previously described by PET/CT and histology. D. choledochus and D. pancreaticus major were separated intraoperatively by ultrasound. 3 of 5 patients were cured by complete enucleation of the focus. Nevertheless, the entire intraoperative identification of the segmented focus is still problematic. Characteristic sonographic features of a CHI focus are: hypoechogenicity, variable homogeneous and inhomogenous texture, blurred, irregular limitation without capsule, filiform, lobular processes, and insular dispersal into the surrounding tissue. Intraoperative high-resolution sonography helps the pediatric surgeon to determine size, configuration and topography of a CHI focus.
Asunto(s)
Procesamiento de Imagen Asistido por Computador/métodos , Nesidioblastosis/diagnóstico por imagen , Nesidioblastosis/cirugía , Páncreas/diagnóstico por imagen , Páncreas/cirugía , Ultrasonografía/métodos , Conducto Colédoco/diagnóstico por imagen , Conducto Colédoco/cirugía , Diseño de Equipo , Femenino , Humanos , Procesamiento de Imagen Asistido por Computador/instrumentación , Imagenología Tridimensional , Lactante , Células Secretoras de Insulina/diagnóstico por imagen , Periodo Intraoperatorio , Masculino , Conductos Pancreáticos/diagnóstico por imagen , Conductos Pancreáticos/cirugía , Tomografía de Emisión de Positrones , Sensibilidad y Especificidad , Tomografía Computarizada por Rayos X , Ultrasonografía/instrumentaciónRESUMEN
Infants with congenital hyperinsulinism may require a positron emission tomography examination with 18F-labeled L-DOPA for the evaluation and planning of surgical interventions. To obtain optimal results it is important for the child to be in a stress-free situation because a stable glucose homoeostasis must be maintained by intravenous glucose infusion. The infant needs to lie calm over a long period of time to obtain optimal results. Sedation for this purpose can be achieved with a continuous infusion of propofol and should be carried out by an anesthesiologist. Additionally blood glucose measurements must be regularly carried out and the glucose infusion must be adjusted to prevent hypoglycemia.
Asunto(s)
Sedación Consciente , Hiperinsulinismo/congénito , Glucemia/metabolismo , Dihidroxifenilalanina/análogos & derivados , Femenino , Glucosa/administración & dosificación , Glucosa/metabolismo , Glucosa/uso terapéutico , Homeostasis , Humanos , Hiperinsulinismo/diagnóstico por imagen , Hipnóticos y Sedantes , Lactante , Infusiones Intravenosas , Masculino , Tomografía de Emisión de Positrones , Medicación Preanestésica , Propofol , Radiofármacos , Tomografía Computarizada por Rayos XRESUMEN
In recent years, considerable progress has been made in the biochemical, morphological and molecular genetic differentiation of congenital hyperinsulinism (CHI). Fluorine-18 L-3,4-dihydroxyphenylalanine positron emission tomography ((18)F-DOPA-PET) has been introduced for differentiation between focal and diffuse CHI. The ability to take up L-DOPA and convert it into dopamine is correlated with the activity of the aromatic amino acid decarboxylase and increased in the hyperfunctional affected pancreatic area in comparison to normally functioning pancreas. The high sensitivity of this method allows the surgeon to perform a curative limited resection of a focus without the risk of long-term diabetes. The exact preoperative planning by (18)F-DOPA-PET/CT computer tomography allows laparoscopic operation in selected cases with the focus in the tail and limits necessity to open the pancreatic duct in cases with focus in the head. Patients with persistent CHI should be managed within a strong network of diagnostic, treatment, and research institutions.
Asunto(s)
Hiperinsulinismo Congénito/diagnóstico , Dihidroxifenilalanina , Radioisótopos de Flúor , Tomografía de Emisión de Positrones , Algoritmos , Hiperinsulinismo Congénito/cirugía , Humanos , Páncreas/cirugía , Cuidados PreoperatoriosRESUMEN
BACKGROUND: Congenital hyperinsulinism (CHI) is characterized by severe hypoglycemia caused by dysregulated insulin secretion. The long-term outcome is dependent on prevention of hypoglycemic episodes to avoid the high risk of permanent brain damage. Severe cases are usually resistant to diazoxide or nifedipine. In addition, somatostatin analogues are ineffective in a subgroup of patients to achieve stable euglycemia. In these infants the only remaining long-term option has been subtotal pancreatectomy with high risk of diabetes mellitus. Intravenous infusions of glucagon are used as immediate treatment to stabilize euglycemia in affected newborns. The rationale of this treatment comes from the observation of an increased glycogen content of the liver when glycogenolysis is inhibited by insulin. OBJECTIVE: To review the efficacy and safety of long-term subcutaneous glucagon infusion as a potential therapeutic option for blood glucose stabilization in infants with severe CHI without the need of additional intravenous glucose or immediate surgical intervention. METHOD: Retrospective review of 9 children with CHI who received continuous subcutaneous infusion of glucagon for weeks or months. Glucagon was added to octreotide to replace octreotide-induced suppression of endogenous glucagon secretion, thereby liberating glucose by stimulation of hepatic glycogenolysis. In 3 cases, a stabilized formulation of glucagon was used to prevent glucagon crystallization that frequently occurs in smaller volumes. RESULTS: Introduction of glucagon allowed the reduction or discontinuation of central glucose infusion in all children studied. In 2 patients, glucagon was introduced due to recurrent hypoglycemia despite subtotal pancreatectomy. Six out of 9 children were discharged home on this treatment, which their parents were able to continue without further symptomatic hypoglycemia, convulsions or unconsciousness. In 3 children, subcutaneous glucagon was continuously administered for 1-4 years leading to stable euglycemia. However, 2 children with diffuse type still required subtotal pancreatectomy. As a possible side effect, 2 children developed erythema necrolyticum, which resolved after discontinuation of the glucagon infusion. This has been described before in glucagonoma. CONCLUSION: In this retrospective series, combination therapy of low-dose octreotide and subcutaneous glucagon infusion has been effective in preventing hypoglycemic episodes in severe CHI. We propose this may serve as a therapeutic option in place of high rates of glucose infusion through a central venous catheter and as an alternative to subtotal pancreatectomy in diffuse type of CHI.
Asunto(s)
Hiperinsulinismo Congénito/tratamiento farmacológico , Fármacos Gastrointestinales/administración & dosificación , Glucagón/administración & dosificación , Octreótido/administración & dosificación , Glucemia/análisis , Encefalopatías Metabólicas/sangre , Encefalopatías Metabólicas/prevención & control , Hiperinsulinismo Congénito/sangre , Hiperinsulinismo Congénito/complicaciones , Femenino , Fármacos Gastrointestinales/efectos adversos , Glucagón/efectos adversos , Glucógeno/metabolismo , Humanos , Hipoglucemia/sangre , Hipoglucemia/prevención & control , Recién Nacido , Masculino , Octreótido/efectos adversos , Pancreatectomía , Estudios RetrospectivosAsunto(s)
Dihidroxifenilalanina , Dopaminérgicos , Hiperinsulinismo/congénito , Neoplasias Pancreáticas/congénito , Humanos , Hiperinsulinismo/diagnóstico por imagen , Interpretación de Imagen Asistida por Computador , Recién Nacido , Masculino , Neoplasias Pancreáticas/diagnóstico por imagen , Cintigrafía , Resultado del TratamientoAsunto(s)
Hiperinsulinismo Congénito/diagnóstico por imagen , Radioisótopos de Flúor , Levodopa , Tomografía de Emisión de Positrones/métodos , Hiperinsulinismo Congénito/clasificación , Diagnóstico Diferencial , Humanos , Lactante , Páncreas/diagnóstico por imagen , Tomografía de Emisión de Positrones/normas , Sensibilidad y Especificidad , Encuestas y CuestionariosRESUMEN
Mutations of the PROP-1 gene cause combined pituitary hormone deficiency. Progressive ACTH/cortisol insufficiency is found in a few patients. Congenital hypoplasia of the anterior pituitary gland is the most common magnetic resonance imaging finding in patients with PROP-1 mutations. We present two brothers with compound heterozygosity for the two mutations 150delA and 301-302delAG of the PROP-1 gene. Both showed combined pituitary hormone deficiency of GH, TSH, PRL, and gonadotropins, as is typical for PROP-1 deficiency. We observed a developing insufficiency of ACTH and cortisol secretory capacity in both patients. Computed tomography revealed an enlarged pituitary in the older brother at 3.5 yr of age. Repeated magnetic resonance imaging after 12 yr showed a constant hypoplasia of the anterior pituitary lobe. Similarly, magnetic resonance imaging of the younger brother showed a constant enlargement of the anterior pituitary gland until 10 yr. At the age of 11 yr, the anterior pituitary was hypoplastic. The reason for pituitary enlargement in early childhood with subsequent decrease in pituitary size is not known. We speculate that altered expression of early transcription factors could be involved. Because both patients have the same PROP-1 mutations and an identical pattern of combined pituitary hormone deficiency, we suggest that early pituitary enlargement may be the typical course in such patients in whom pituitary surgery is not indicated.
Asunto(s)
Proteínas de Homeodominio/genética , Hiperpituitarismo/genética , Hiperpituitarismo/patología , Hipopituitarismo/genética , Hipopituitarismo/patología , Mutación/fisiología , Hipófisis/patología , Factores de Transcripción/genética , Niño , Preescolar , ADN/genética , Femenino , Genoma , Humanos , Hiperpituitarismo/diagnóstico por imagen , Hipopituitarismo/diagnóstico por imagen , Lactante , Estudios Longitudinales , Imagen por Resonancia Magnética , Masculino , Hipófisis/diagnóstico por imagen , Hormonas Hipofisarias/sangre , Hormonas Hipofisarias/deficiencia , Estudios Prospectivos , Tomografía Computarizada por Rayos XRESUMEN
OBJECTIVE: We describe a newborn with clinical signs of severe hypothyroidism and combined pituitary hormone deficiency due to a new mutation in the PIT-1 gene. PATIENT AND METHODS: Endocrine stimulation test revealed a deficiency for PRL, TSH and GH, suggesting a defect in the pituitary transcription factor PIT-1. Genetic analysis of the PIT-1 gene was performed by exon-specific PCR, followed by SSCP mutation screening and DNA sequencing of the abnormal migrating fragments. RESULTS: DNA sequencing revealed a new mutation (V272ter) in direct neighborhood to a known mutational hot spot (R271W) in the C-terminal part of the PIT-1 molecule. CONCLUSIONS: Whereas the R271W mutation has a dominant negative effect on the mutant protein, the newly described mutation is inherited in an autosomal-recessive way. The biological consequences of these two different mutations are discussed.
Asunto(s)
Hipotiroidismo Congénito , Proteínas de Unión al ADN/genética , Hipotiroidismo/genética , Mutación/genética , Factores de Transcripción/genética , Secuencia de Bases/genética , Genes Recesivos , Humanos , Lactante , Masculino , Polimorfismo Conformacional Retorcido-Simple , Factor de Transcripción Pit-1RESUMEN
Some non-organic causes for growth hormone (GH) deficiency (GHD) can be attributed to genetic defects within the hypothalamo-pituitary axis. Using modern molecular biology techniques micromutations within the GH and GH-releasing hormone receptor genes have been detected as a rare cause of isolated GHD. Combined pituitary hormone deficiencies (CPHD), on the other hand, are associated with defects that manifest during the organogenesis of the anterior pituitary gland. In recent years an increasing number of patients with CPHD has been reported, showing mutations within pituitary transcription factors Pit-1, Prop-1 and HesX1. Such defects can be observed with different frequencies in patients. Some disorders, such as CPHD due to Pit-1 mutations, display a hormonal phenotype that seems more or less invariable. In most other forms of genetic CPHD both the combination and severity of anterior pituitary hormone deficiencies vary considerably. Ongoing research concentrates on factors involved in the differentiation and proliferation of cells that belong to the hypothalamo-pituitary growth axis. As not every possible candidate turns out to be a frequent cause of GHD or CPHD in humans, it will be many more years before the term 'idiopathic' becomes a vanishing attribute to the clinical diagnosis of pituitary insufficiency.
Asunto(s)
Hormona de Crecimiento Humana/deficiencia , Enfermedades de la Hipófisis/diagnóstico , Animales , Hormona de Crecimiento Humana/genética , Humanos , Enfermedades de la Hipófisis/genéticaRESUMEN
During fetal development of the anterior pituitary gland, a number of sequential processes occur that affect cell differentiation and proliferation. Molecular analyses have revealed several steps that are required for pituitary cell line specification and have identified specific factors that control these steps. The gene encoding the pituitary transcription factor 1 (Pit-1) is expressed during differentiation steps that take place quite late in the development of the anterior pituitary gland. Clinically, patients with mutations of the PIT1 gene are characterized by severe deficiencies in growth hormone (GH) and prolactin (PRL), and often develop secondary hypothyroidism. A second pituitary transcription factor is known as Prophet of Pit-1 (Prop-1), and a mutation of the Prop1 gene has been detected in Ames dwarf mice. Several Prop1 mutations have been identified that structurally affect the 'paired-like' DNA-binding domain of the Prop-1 protein molecule. Patients with PROP1 mutations show combined pituitary hormone deficiency. These patients exhibit secondary hypogonadism in addition to the deficiencies of GH, PRL and thyroid-stimulating hormone (TSH) also seen in patients with PIT1 mutations. Although all are in the subnormal range, the levels of GH, PRL and TSH in patients with PROP1 mutations are, on average, slightly higher than in patients with PIT1 mutations. Some degree of hypocortisolism may necessitate cortisol substitution in patients with PROP1 mutations.
Asunto(s)
Proteínas de Unión al ADN/genética , Proteínas de Homeodominio/genética , Hormonas Hipofisarias/deficiencia , Factores de Transcripción/genética , Transcripción Genética , Animales , Arginina/genética , Humanos , Ratones , Mutación , Fenotipo , Factor de Transcripción Pit-1 , Triptófano/genéticaRESUMEN
The pituitary transcription factor Pit-1 is expressed during the later differentiation stages of anterior pituitary development and Pit-1 mutations have been identified as the cause of a combined pituitary hormone deficiency (CPHD) for GH, prolactin and TSH. Mutations within the human Pit-1 gene can either impair the DNA binding of this transcription factor, or while leaving DNA binding capabilities unimpaired, decrease its function within the transactivation complex. Approximately half of all patients with this phenotype do not show any defect within the Pit-1 gene. Prop-1, a recently discovered transcription factor of anterior pituitary development, seemed a likely candidate for such mutations. Prop-1 mutations, however, have been found so far to induce a combined pituitary hormone deficiency for GH, prolactin, TSH and gonadotropins. We describe here a group of patients with isolated and combined pituitary hormone deficiencies who were screened for Pit-1 and Prop-1 mutations to characterize the phenotypic spectrum of defects within these two genes.
Asunto(s)
Proteínas de Unión al ADN/fisiología , Proteínas de Homeodominio/fisiología , Hormona de Crecimiento Humana/genética , Hipopituitarismo/genética , Factores de Transcripción/fisiología , Animales , Proteínas de Unión al ADN/química , Proteínas de Unión al ADN/genética , Modelos Animales de Enfermedad , Regulación del Desarrollo de la Expresión Génica , Proteínas de Homeodominio/química , Proteínas de Homeodominio/genética , Hormona de Crecimiento Humana/deficiencia , Hormona de Crecimiento Humana/fisiología , Humanos , Hipopituitarismo/fisiopatología , Mutación/genética , Fenotipo , Adenohipófisis/anomalías , Adenohipófisis/embriología , Adenohipófisis/metabolismo , Hormonas Adenohipofisarias/deficiencia , Hormonas Adenohipofisarias/genética , Hormonas Adenohipofisarias/fisiología , Factor de Transcripción Pit-1 , Factores de Transcripción/química , Factores de Transcripción/genéticaRESUMEN
An internal fragment of the cfb gene from group B streptococcal (GBS) strain R268 was amplified by polymerase chain reaction (PCR) using degenerate primers with sequences derived from the CAMP-factor amino acid (aa) sequence of GBS strain NCTC8181 [Rühlmann et al. (1988) FEBS Lett 235:262-266]. After cloning and sequencing this fragment, the remainder of cfb and the adjacent 5' and 3' sequences were amplified by inverted PCR of genomic DNA and directly sequenced from the PCR product. Within the 1560 bp sequenced, a complete cfb gene deviating in two deduced aa residues from the published sequence was identified. In addition, the cfbR268 sequence contained a 29-aa leader peptide. Using primers directed to the 5' and 3' ends of cfb for PCR, a cfb gene of uniform size could be detected in 19 clinical GBS isolates including three phenotypically CAMP-negative strains. Utilizing Northern blot analysis and primer extension assays, the cfbR268 promoter was located and the length of the cfb transcript was assessed at about 1100 bp. In a parallel experiment, no cfb transcript could be detected from the CAMP-negative GBS strain 74-360. The complete cfbR268 gene and different portions of its 5' and 3' ends were cloned into the plasmid pJLA602 and expressed in E. coli DH5 alpha. The recombinant peptides could be detected by Western immunoblots with polyclonal antiserum. Only the full-sized recombinant CAMP-factor was found to exert co-hemolytic activity in a sheep-blood agar assay. This co-hemolytic activity could be inhibited by anti-CAMP antiserum.